
  
    
      
        Background_NNP
        Cytosolic_NNP PLA_NNP 
        2_CD specifically_RB hydrolyzes_NNS 
        sn-_NN 2_CD arachidonate_NN from_IN phospholipid_NN
        providing_VBG the_DT precursors_NNS for_IN many_JJ different_JJ lipid_NN mediators_NNS
        including_VBG prostaglandins_NNS and_CC leukotrienes_NNS [_NN 1_CD 2_CD ]_NN ._. These_DT
        lipid_NN metabolites_NNS play_VBP a_DT role_NN in_IN acute_JJ inflammatory_JJ
        responses_NNS and_CC also_RB regulate_VB normal_JJ physiological_JJ processes_NNS ._.
        Certain_JJ prostaglandins_NNS are_VBP required_VBN for_IN female_JJ reproduction_NN
        and_CC kidney_NN function_NN [_NN 3_CD 4_CD 5_CD ]_NN ._. Because_IN of_IN its_PRP$ important_JJ
        role_NN in_IN controlling_VBG levels_NNS of_IN arachidonic_JJ acid_NN (_( AA_NN )_) ,_, much_JJ
        attention_NN has_VBZ been_VBN focused_VBN on_IN the_DT regulation_NN of_IN cPLA_NN 
        2_CD activation_NN ,_, with_IN particular_JJ emphasis_NN
        on_IN the_DT role_NN of_IN its_PRP$ phosphorylation_NN and_CC Ca_MD 2_CD +_NN -_: mediated_JJ
        translocation_NN [_NN 6_CD 7_CD 8_CD ]_NN ._.
        cPLA_NN 
        2_CD is_VBZ regulated_VBN by_IN controlling_VBG its_PRP$
        cellular_JJ localization_NN and_CC access_NN to_TO membrane-phospholipid_JJ
        substrate_NN ._. An_DT amino_JJ terminal_NN ,_, calcium-dependent_JJ lipid_NN
        binding_JJ (_( CaLB_NNP or_CC C_NNP 2_LS )_) domain_NN regulates_VBZ Ca_MD 2_CD +_NN -_: mediated_JJ cPLA_NN 
        2_CD translocation_NN to_TO intracellular_NN
        membranes_NNS [_NN 9_CD ]_NN ._. In_IN vitro_NN ,_, membrane_NN docking_VBG via_IN the_DT C_NNP 2_CD
        domain_NN is_VBZ necessary_JJ and_CC sufficient_JJ for_IN catalysis_NNS and_CC
        release_NN of_IN AA_NN [_NN 10_CD ]_NN ._. Binding_NNP of_IN calcium_NN ions_NNS by_IN the_DT cPLA_NN 
        2_CD C_NNP 2_CD domain_NN is_VBZ essential_JJ for_IN the_DT lipid_NN
        association_NN in_IN vitro_NN [_NN 11_CD 12_CD ]_NN and_CC translocation_NN in_IN vivo_NN [_NN
        13_CD 14_CD ]_NN ._. In_IN response_NN to_TO an_DT increase_NN in_IN [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP ,_, cPLA_NN 
        2_CD translocates_NNS to_TO the_DT Golgi_NNP and_CC ER_NNP ,_,
        however_RB translocation_NN to_TO Golgi_NNP occurs_VBZ at_IN a_DT lower_JJR [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP [_NN 15_CD ]_NN ._.
        Protein_NNP kinase_NN pathways_NNS play_VBP major_JJ roles_NNS in_IN cPLA_NN 
        2_CD activation_NN ,_, and_CC regulation_NN by_IN the_DT
        mitogen-activated_JJ protein_NN kinase_NN kinase_NN (_( MEK_NNP )_)
        /_NN extracellular-signal_JJ regulated_VBN kinase_NN (_( ERK_NNP )_) signaling_VBG
        pathway_NN has_VBZ received_VBN particular_JJ attention_NN ._. cPLA_NN 
        2_CD is_VBZ phosphorylated_JJ by_IN mitogen_NN activated_VBN
        protein_NN (_( MAP_NNP )_) kinases_NNS ,_, including_VBG p_NN 42_CD /_NN p_NN 44_CD ERKs_NNP and_CC p_NN 38_CD ,_, on_IN
        Ser_NNP 505_CD in_IN vitro_NN [_NN 16_CD 17_CD ]_NN and_CC in_IN response_NN to_TO receptor_NN
        stimulation_NN [_NN 16_CD 18_CD 19_CD 20_CD 21_CD ]_NN ._. In_IN addition_NN to_TO
        phosphorylation_NN by_IN MAP_NNP kinase_NN ,_, it_PRP has_VBZ been_VBN shown_VBN that_DT cPLA_NN 
        2_CD is_VBZ also_RB phosphorylated_JJ on_IN Ser_NNP 727_NNP by_IN
        MAPK-interacting_NNP kinase_NN I_PRP (_( MNKI_NNP )_) [_NN 22_CD ]_NN and_CC on_IN Ser_NNP 515_CD by_IN
        calcium_NN /_NN calmodulin-dependent_JJ protein_NN kinase_NN II_NNP [_NN 23_CD ]_NN ._.
        Phosphorylation_NNP of_IN these_DT sites_NNS may_MD also_RB play_VB a_DT role_NN in_IN
        regulating_VBG cPLA_NN 
        2_CD function_NN in_IN certain_JJ cell_NN models_NNS ._.
        Phosphorylation_NNP of_IN Ser_NNP 505_CD has_VBZ been_VBN extensively_RB studied_VBN
        because_IN it_PRP is_VBZ readily_RB detected_VBN due_JJ to_TO a_DT characteristic_JJ
        electrophoretic_JJ mobility_NN shift_NN when_WRB analyzed_VBN by_IN SDS-PAGE_NNP [_NN
        13_CD 16_CD ]_NN ._. The_DT importance_NN of_IN Ser_NNP 505_CD phosphorylation_NN in_IN
        regulating_VBG cPLA_NN 
        2_CD has_VBZ been_VBN demonstrated_VBN in_IN different_JJ
        cells_NNS and_CC in_IN vitro_NN models_NNS by_IN using_VBG cPLA_NN 
        2_CD containing_VBG a_DT S_NNP 505_CD A_DT mutation_NN [_NN 16_CD 22_CD ]_NN
        ._. However_RB ,_, the_DT mechanism_NN whereby_WRB Ser_NNP 505_CD phosphorylation_NN
        regulates_VBZ cPLA_NN 
        2_CD function_NN has_VBZ been_VBN elusive_JJ ._. In_IN vitro_NN
        studies_NNS have_VBP demonstrated_VBN that_IN dephosphorylated_JJ cPLA_NN 
        2_CD is_VBZ catalytically_RB active_JJ and_CC that_IN Ser_NNP
        505_CD phosphorylation_NN increases_NNS activity_NN by_IN only_RB ~_NN 30_CD percent_NN [_NN
        24_CD ]_NN ._. In_IN contrast_NN ,_, cells_NNS expressing_VBG the_DT cPLA_NN 
        2_CD S_NNP 505_CD A_DT mutation_NN fail_VB to_TO release_VB AA_NN in_IN
        response_NN to_TO a_DT low_JJ dose_NN of_IN calcium_NN ionophore_NN ,_, but_CC release_VB
        similar_JJ amounts_NNS of_IN AA_NN as_IN cells_NNS expressing_VBG wild-type_JJ cPLA_NN 
        2_CD in_IN response_NN to_TO high_JJ dose_NN ionophore_NN [_NN
        22_CD ]_NN ._. From_IN these_DT studies_NNS ,_, it_PRP has_VBZ been_VBN suggested_VBN that_DT cPLA_NN 
        2_CD Ser_NNP 505_CD phosphorylation_NN may_MD have_VB a_DT role_NN
        in_IN regulating_VBG translocation_NN [_NN 22_CD ]_NN ._. A_DT previous_JJ study_NN
        demonstrated_VBD translocation_NN of_IN cPLA_NN 
        2_CD S_NNP 505_CD A_DT in_IN response_NN to_TO Ca_MD 2_CD +_NN ionophore_NN ,_,
        but_CC did_VBD not_RB address_VB the_DT kinetics_NNS of_IN translocation_NN ,_,
        translocation_NN in_IN response_NN to_TO a_DT physiological_JJ agonist_NN ,_, or_CC
        differences_NNS in_IN targeting_VBG [_NN 25_CD ]_NN ._.
        To_TO better_JJR understand_VB the_DT regulation_NN of_IN cPLA_NN 
        2_CD by_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN and_CC Ca_MD 2_CD +_NN ,_, we_PRP
        investigated_VBD the_DT effect_NN of_IN MEK_NNP inhibitors_NNS on_IN AA_NN release_NN ,_,
        cPLA_NN 
        2_CD phosphorylation_NN of_IN Ser_NNP 505_CD ,_, cPLA_NN 
        2_CD translocation_NN kinetics_NNS ,_, and_CC [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP increase_NN in_IN Madin-_NNP Darby_NNP canine_JJ kidney_NN
        (_( MDCK_NNP )_) cells_NNS ._. We_PRP found_VBD that_DT inhibition_NN of_IN MEK_NNP 1_CD by_IN U_NNP 0126_CD
        significantly_RB inhibited_VBD AA_NN release_NN and_CC this_DT was_VBD correlated_JJ
        with_IN inhibition_NN of_IN ERK_NNP activation_NN ._. However_RB ,_, MEK_NNP inhibition_NN
        only_RB partially_RB affected_VBN cPLA_NN 
        2_CD phosphorylation_NN and_CC had_VBD no_DT effect_NN on_IN
        the_DT kinetics_NNS of_IN Ca_MD 2_CD +_NN -_: mediated_JJ cPLA_NN 
        2_CD translocation_NN to_TO membrane_NN ._. In_IN
        addition_NN ,_, using_VBG cells_NNS expressing_VBG wild-type_JJ cPLA_NN 
        2_CD and_CC cPLA_NN 
        2_CD with_IN S_NNP 505_CD A_DT or_CC S_NNP 727_NNP A_DT mutations_NNS ,_, it_PRP was_VBD
        found_VBN that_IN translocation_NN kinetics_NNS and_CC membrane_NN targeting_VBG in_IN
        response_NN to_TO ATP_NNP or_CC ionomycin_NN was_VBD similar_JJ to_TO wild-type_JJ cPLA_NN 
        2_CD ._. These_DT data_NNS suggest_VBP that_IN MEK_NNP 1_CD
        inhibition_NN reduces_VBZ cPLA_NN 
        2_CD catalytic_JJ activity_NN and_CC AA_NN release_NN
        independently_RB of_IN phosphorylation_NN and_CC translocation_NN ._.
      
      
        Results_NNS
        
          Effect_NN of_IN MEK_NNP inhibition_NN on_IN AA_NN release_NN ,_, ERK_NNP
          activation_NN ,_, and_CC cPLA_NN 2_CD Ser_NNP 505_CD phosphorylation_NN
          To_TO study_VB the_DT role_NN of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN in_IN cPLA_NN 
          2_CD activation_NN ,_, quiesced_JJ MDCK_NNP cells_NNS were_VBD
          treated_VBN with_IN the_DT MEK_NNP 1_CD inhibitor_NN U_NNP 0126_CD ,_, and_CC the_DT effect_NN on_IN
          AA_NN release_NN ,_, ERK_NNP activation_NN ,_, and_CC cPLA_NN 
          2_CD gel_NN shift_NN determined_VBN (_( Fig_NNP ._. 1_LS )_) ._. For_IN
          equivalence_NN with_IN the_DT imaging_NN studies_NNS ,_, cells_NNS expressing_VBG
          EGFP-cPLA_NNP 
          2_CD were_VBD used_VBN in_IN all_DT experiments_NNS ._.
          EGFP-cPLA_NNP 
          2_CD was_VBD expressed_VBN to_TO similar_JJ levels_NNS as_IN
          endogenous_JJ enzyme_NN but_CC did_VBD not_RB contribute_VB significantly_RB to_TO
          AA_NN release_NN in_IN stably_RB transfected_JJ cells_NNS ._. However_RB ,_,
          EGFP-cPLA_NNP 
          2_CD is_VBZ functional_JJ since_IN it_PRP
          dose-dependently_JJ catalyzes_NNS release_NN of_IN AA_NN when_WRB expressed_VBD
          in_IN cells_NNS that_WDT lack_NN endogenous_JJ cPLA_NN 
          2_CD ,_, such_JJ as_IN Sf_NNP 9_CD cells_NNS [_NN 13_CD ]_NN and_CC
          immortalized_JJ mouse_NN lung_NN fibroblasts_NNS from_IN cPLA_NN 
          2_CD α_NN knock-out_JJ mice_NNS [_NN 26_CD ]_NN ._. In_IN order_NN
          to_TO enhance_VB AA_NN release_NN in_IN cells_NNS containing_VBG endogenous_JJ cPLA_NN
          
          2_LS ,_, it_PRP is_VBZ necessary_JJ to_TO over-express_JJ
          the_DT enzyme_NN several_JJ fold_VB as_RB previously_RB reported_VBD [_NN 16_CD ]_NN ._.
          Cytosolic_NNP PLA_NNP 
          2_CD has_VBZ been_VBN shown_VBN to_TO mediate_VB Ca_MD
          2_CD +_NN -_: induced_VBN AA_NN release_NN in_IN MDCK_NNP cells_NNS treated_VBN with_IN ATP_NNP and_CC
          IONO_NNP in_IN experiments_NNS using_VBG the_DT group_NN IV_NNP cPLA_NN 
          2_CD α-specific_JJ inhibitor_NN pyrrolidine-_NN 1_CD [_NN
          27_CD ]_NN ._. To_TO measure_VB cPLA_NN 
          2_CD mediated_JJ AA_NN release_NN ,_, EGFP-cPLA_NNP 
          2_CD -_: transfected_JJ MDCK_NNP cells_NNS labeled_VBN with_IN
          [_NN 3_CD H_NNP ]_NN -_: AA_NN were_VBD incubated_JJ with_IN 0_CD ._. 3_CD ,_, 1_CD or_CC 10_CD μM_NN U_NNP 0126_CD for_IN 15_CD
          min_NN prior_RB to_TO stimulation_NN with_IN 100_CD μM_NN ATP_NNP ,_, 1_CD μM_NN IONO_NNP ,_, or_CC
          10_CD μM_NN IONO_NNP ._. AA_NN release_NN was_VBD measured_VBN at_IN 3_CD min_NN because_IN we_PRP
          have_VBP shown_VBN that_IN ATP-_NNP and_CC IONO-stimulated_NNP AA_NN release_NN peaks_NNS
          between_IN 3_CD to_TO 5_CD min_NN post-stimulation_JJ [_NN 15_CD ]_NN ._.
          Agonist-induced_NNP AA_NN release_NN was_VBD inhibited_VBD dose-dependently_JJ
          by_IN U_NNP 0126_CD (_( Fig_NNP ._. 1_LS A_DT )_) with_IN the_DT highest_JJS U_NNP 0126_CD concentration_NN
          used_VBN (_( 10_CD μM_NN )_) reducing_VBG AA_NN release_NN by_IN 72_CD -_: 80_CD %_NN with_IN all_DT
          agonists_NNS (_( Table_NNP I_PRP )_) ._. This_DT inhibition_NN was_VBD independent_JJ of_IN
          the_DT total_JJ amount_NN of_IN AA_NN released_VBD ,_, since_IN AA_NN release_NN
          stimulated_VBN by_IN 10_CD μM_NN IONO_NNP was_VBD 3_CD -_: fold_VB greater_JJR than_IN release_NN
          stimulated_VBN with_IN 1_CD μM_NN IONO_NNP or_CC 100_CD μM_NN ATP_NNP ,_, but_CC the_DT percent_NN
          inhibition_NN by_IN U_NNP 0126_CD was_VBD similar_JJ ._. Treatment_NNP of_IN MDCK_NNP cells_NNS
          with_IN 30_CD μM_NN PD_NNP 098059_CD ,_, a_DT less_RBR potent_JJ inhibitor_NN of_IN MEK_NNP [_NN 28_CD
          29_CD ]_NN ,_, resulted_VBD in_IN a_DT ~_NN 50_CD %_NN reduction_NN in_IN AA_NN release_NN in_IN
          response_NN to_TO 100_CD μM_NN ATP_NNP ,_, 1_CD μM_NN IONO_NNP ,_, and_CC 10_CD μM_NN IONO_NNP (_( data_NNS
          not_RB shown_VBN )_) ._. Thus_RB ,_, in_IN MDCK_NNP cells_NNS ,_, MEK_NNP 1_CD inhibition_NN
          significantly_RB reduces_VBZ the_DT ability_NN of_IN cPLA_NN 
          2_CD to_TO hydrolyze_NN AA_NN from_IN membrane_NN
          phospholipids_NNS ._.
          The_DT effect_NN of_IN MEK_NNP 1_CD inhibition_NN on_IN activation_NN of_IN p_NN 42_CD /_NN p_NN 44_CD
          ERK_NNP measured_VBN by_IN immunoblot_NN analysis_NN using_VBG
          phospho-specific_JJ antibodies_NNS in_IN cells_NNS treated_VBN with_IN U_NNP 0126_CD
          and_CC stimulated_VBN as_IN above_IN was_VBD determined_VBN (_( Fig_NNP ._. 1_LS B_NNP )_) ._. Work_NN in_IN
          our_PRP$ laboratory_NN has_VBZ shown_VBN that_DT recognition_NN of_IN ERK_NNP by_IN
          anti-phospho-_JJ ERK_NNP antibodies_NNS correlates_NNS with_IN an_DT increase_NN
          in_IN ERK_NNP activity_NN [_NN 21_CD 30_CD 31_CD ]_NN ._. Interestingly_RB ,_, the_DT
          anti-phospho-_JJ ERK_NNP immunoblots_NNS revealed_VBD that_IN ERKs_NNP were_VBD
          constitutively_RB activated_VBN in_IN untreated_JJ ,_, quiesced_JJ MDCK_NNP
          cells_NNS and_CC activation_NN was_VBD not_RB enhanced_VBN further_RB by_IN ATP_NNP or_CC
          IONO_NNP (_( Fig_NNP ._. 1_LS B_NNP ,_, left_VBD panel_NN )_) ._. ERK_NNP activation_NN was_VBD diminished_VBN
          by_IN increasing_VBG concentrations_NNS of_IN U_NNP 0126_CD and_CC was_VBD
          quantitatively_RB inhibited_VBD after_IN 15_CD min_NN incubation_NN in_IN 10_CD μM_NN
          U_NNP 0126_CD ._. U_NNP 0126_CD decreased_VBD ERK_NNP activation_NN following_VBG ATP_NNP or_CC
          IONO_NNP stimulation_NN in_IN the_DT same_JJ fashion_NN as_IN in_IN unstimulated_JJ
          cells_NNS ._. Consequently_RB ,_, there_EX was_VBD a_DT direct_JJ correlation_NN
          between_IN the_DT reduction_NN of_IN AA_NN release_NN (_( Fig_NNP ._. 1_LS A_DT )_) and_CC
          inhibition_NN of_IN ERK_NNP activation_NN (_( Fig_NNP ._. 1_LS B_NNP )_) in_IN MDCK_NNP cells_NNS
          treated_VBN with_IN U_NNP 0126_CD ._.
          Because_IN cPLA_NN 
          2_CD is_VBZ a_DT target_NN of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP
          signaling_VBG cascade_NN ,_, we_PRP assayed_JJ the_DT effect_NN of_IN MEK_NNP 1_CD
          inhibition_NN by_IN U_NNP 0126_CD on_IN cPLA_NN 
          2_CD phosphorylation_NN by_IN analyzing_VBG gel_NN
          shift_NN of_IN cPLA_NN 
          2_CD ._. Phosphorylation_NNP of_IN Ser_NNP 505_CD results_NNS
          in_IN a_DT retardation_NN of_IN its_PRP$ electrophoretic_JJ mobility_NN (_( gel_NN
          shift_NN )_) [_NN 13_CD 16_CD ]_NN ._. In_IN unstimulated_JJ cells_NNS ,_, EGFP-tagged_NNP and_CC
          endogenous_JJ cPLA_NN 
          2_CD were_VBD nearly_RB completely_RB gel_NN shifted_VBD ,_,
          indicating_VBG that_IN most_JJS cPLA_NN 
          2_CD was_VBD phosphorylated_JJ on_IN Ser_NNP 505_CD (_( Fig_NNP ._.
          1_LS C_NNP )_) ,_, which_WDT is_VBZ consistent_JJ with_IN the_DT observation_NN that_IN ERKs_NNP
          are_VBP constitutively_RB activated_VBN ._. Incubation_NNP with_IN U_NNP 0126_CD
          resulted_VBD in_IN a_DT partial_JJ reversal_NN of_IN the_DT gel_NN shift_NN although_IN ,_,
          at_IN 10_CD μM_NN U_NNP 0126_CD ,_, approximately_RB half_NN of_IN cPLA_NN 
          2_CD remained_VBD phosphorylated_JJ on_IN Ser_NNP 505_CD ._.
          Thus_RB ,_, unlike_IN the_DT quantitative_JJ effect_NN of_IN U_NNP 0126_CD on_IN ERK_NNP
          activation_NN ,_, inhibition_NN of_IN MEK_NNP 1_CD with_IN U_NNP 0126_CD only_RB partially_RB
          reversed_VBD the_DT gel_NN shift_NN of_IN cPLA_NN 
          2_CD ._. The_DT reversal_NN of_IN the_DT gel_NN shift_NN was_VBD
          similar_JJ in_IN cells_NNS treated_VBN with_IN ATP_NNP and_CC 1_CD and_CC 10_CD μM_NN IONO_NNP ._.
          Due_JJ to_TO the_DT increased_VBN molecular_JJ weight_NN of_IN the_DT EGFP-tagged_NNP
          cPLA_NN 
          2_CD ,_, the_DT two_CD forms_NNS of_IN cPLA_NN 
          2_CD did_VBD not_RB separate_JJ as_IN well_RB ,_, making_VBG the_DT
          gel_NN shift_NN more_RBR difficult_JJ to_TO visualize_VB ,_, but_CC generally_RB
          mirrored_VBD the_DT gel_NN shift_NN characteristics_NNS of_IN the_DT endogenous_JJ
          cPLA_NN 
          2_CD ._. These_DT results_NNS suggest_VBP that_IN ,_, in_IN
          response_NN to_TO MEK_NNP 1_CD inhibition_NN ,_, there_EX is_VBZ a_DT quantitative_JJ ,_,
          dose-dependent_JJ decrease_NN in_IN AA_NN release_NN that_IN correlates_NNS
          well_RB with_IN the_DT loss_NN of_IN ERK_NNP activation_NN ,_, but_CC not_RB with_IN the_DT
          extent_NN of_IN cPLA_NN 
          2_CD Ser_NNP 505_CD phosphorylation_NN ._.
          To_TO further_VB investigate_VB whether_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN
          played_VBD a_DT role_NN in_IN regulating_VBG AA_NN release_NN independent_JJ of_IN Ser_NNP
          505_CD phosphorylation_NN ,_, we_PRP treated_VBD cells_NNS with_IN anisomycin_NN ,_,
          which_WDT activates_NNS the_DT MAPK_NNP homolog_NN p_NN 38_CD ,_, but_CC not_RB the_DT
          MEK_NNP 1_CD /_NN ERK_NNP pathway_NN [_NN 32_CD ]_NN ._. Activation_NNP of_IN p_NN 38_CD in_IN response_NN
          to_TO anisomycin_NN treatment_NN was_VBD analyzed_VBN by_IN immunoblotting_VBG
          using_VBG an_DT anti-phospho-p_JJ 38_CD antibody_NN (_( Fig_NNP ._. 2_LS A_DT )_) ._. The_DT
          immunoblots_NNS demonstrate_VBP that_IN 30_CD min_NN treatment_NN in_IN 25_CD ng_NN /_NN ml_NN
          anisomycin_NN resulted_VBD in_IN phosphorylation_NN of_IN p_NN 38_CD in_IN
          unstimulated_JJ MDCK_NNP cells_NNS and_CC in_IN cells_NNS treated_VBN with_IN ATP_NNP or_CC
          IONO_NNP ._. ATP_NNP and_CC ionomycin_NN treatment_NN in_IN the_DT absence_NN of_IN
          anisomycin_NN only_RB weakly_RB increased_VBN p_NN 38_CD phosphorylation_NN ._. As_IN
          expected_VBN ,_, the_DT MEK_NNP inhibitor_NN U_NNP 0126_CD did_VBD not_RB significantly_RB
          affect_VB anisomycin-stimulated_JJ p_NN 38_CD phosphorylation_NN ._. In_IN
          control_NN experiments_NNS ,_, anisomycin_NN treatment_NN did_VBD not_RB induce_VB
          ERK_NNP activation_NN nor_CC interfere_VB with_IN inhibition_NN of_IN ERK_NNP
          activation_NN by_IN 10_CD μM_NN U_NNP 0126_CD treatment_NN (_( Fig_NNP ._. 2_LS B_NNP )_) ._. We_PRP have_VBP
          previously_RB reported_VBN that_DT p_NN 38_CD is_VBZ also_RB selectively_RB
          activated_VBN in_IN anisomycin-treated_JJ macrophages_NNS [_NN 21_CD ]_NN ._.
          Importantly_NNP ,_, pretreatment_NN of_IN cells_NNS for_IN 30_CD min_NN with_IN
          anisomycin_NN resulted_VBD in_IN maintenance_NN of_IN the_DT cPLA_NN 
          2_CD gel_NN shift_NN in_IN the_DT presence_NN of_IN U_NNP 0126_CD
          in_IN unstimulated_JJ cells_NNS and_CC in_IN cells_NNS stimulated_VBN with_IN ATP_NNP
          and_CC 1_CD and_CC 10_CD μM_NN IONO_NNP (_( Fig_NNP ._. 2_LS C_NNP )_) ._. AA_NN release_NN assays_NNS show_VBP
          that_IN ,_, in_IN MDCK_NNP cells_NNS treated_VBN with_IN anisomycin_NN ,_, U_NNP 0126_CD
          resulted_VBD in_IN an_DT AA_NN release_NN reduction_NN of_IN ~_NN 67_CD -_: 76_CD %_NN (_( Fig_NNP ._. 2_LS D_NNP )_)
          similar_JJ to_TO the_DT inhibition_NN observed_VBD without_IN anisomycin_NN ._.
          These_DT results_NNS demonstrate_VBP that_DT activation_NN of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP
          pathway_NN is_VBZ required_VBN for_IN AA_NN release_NN even_RB under_IN conditions_NNS
          where_WRB cPLA_NN 
          2_CD Ser_NNP 505_CD phosphorylation_NN is_VBZ
          maintained_VBN ,_, suggesting_VBG an_DT alternative_JJ role_NN for_IN the_DT
          MEK_NNP 1_CD /_NN ERK_NNP pathway_NN in_IN regulating_VBG cPLA_NN 
          2_CD ._.
        
        
          [_NN Ca_MD 2_CD +_NN ]_NN iincrease_NN is_VBZ independent_JJ of_IN MEK_NNP 1_CD /_NN ERK_NNP
          pathway_NN
          One_CD explanation_NN for_IN the_DT decrease_NN in_IN AA_NN is_VBZ that_IN U_NNP 0126_CD
          inhibits_NNS [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP mobilization_NN in_IN response_NN to_TO ATP_NNP or_CC
          IONO_NNP ,_, thereby_RB preventing_VBG translocation_NN of_IN cPLA_NN 
          2_CD ._. In_IN chick_NN ventricular_NN myocytes_NNS ,_,
          inhibition_NN of_IN MEK_NNP 1_CD /_NN ERK_NNP by_IN PD_NNP 98059_CD inhibits_NNS
          zinterol-mediated_JJ AA_NN release_NN ,_, but_CC also_RB inhibits_NNS
          zinterol-induced_JJ stimulation_NN of_IN [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP cycling_NN in_IN electrically_RB stimulated_VBN
          cells_NNS [_NN 33_CD ]_NN ._. In_IN MDCK_NNP cells_NNS ,_, extracellular_NN ATP_NNP acts_NNS via_IN
          P_NN 
          2_CD Y_NNP 2_CD receptors_NNS to_TO elicit_NN an_DT IP_NNP 
          3_CD -_: mediated_JJ [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN [_NN 34_CD ]_NN and_CC IONO_NNP acts_NNS to_TO
          increase_VB [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP by_IN permeabilizing_VBG cell_NN membranes_NNS to_TO
          Ca_MD 2_CD +_NN ._. To_TO determine_VB the_DT effect_NN of_IN U_NNP 0126_CD on_IN intracellular_NN
          Ca_MD 2_CD +_NN mobilization_NN by_IN 100_CD μM_NN ATP_NNP or_CC 10_CD μM_NN IONO_NNP ,_, we_PRP
          utilized_JJ single-cell_JJ fluorescence_NN microscopy_NN on_IN cells_NNS
          loaded_VBN with_IN the_DT calcium_NN indicator_NN Fura_NNP 2_CD ._. Analysis_NNP of_IN the_DT
          [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN in_IN individual_JJ cells_NNS reveals_VBZ
          the_DT heterogeneity_NN in_IN the_DT response_NN to_TO ATP_NNP ,_, although_IN most_JJS
          cells_NNS exhibited_VBN [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP spikes_NNS of_IN similar_JJ magnitude_NN and_CC
          duration_NN (_( Fig_NNP ._. 3_LS Aand_NNP 3_CD B_NNP ,_, thin_JJ lines_NNS )_) ._. Analysis_NNP of_IN the_DT [_NN Ca_MD
          2_CD +_NN ]_NN 
          i_NNP increase_NN in_IN several_JJ cells_NNS (_( Fig_NNP ._.
          3_LS Aand_NNP 3_CD B_NNP ,_, thick_JJ line_NN )_) revealed_VBD that_IN although_IN the_DT duration_NN
          of_IN the_DT [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN elicited_JJ by_IN ATP_NNP in_IN control_NN
          cells_NNS was_VBD the_DT same_JJ as_IN in_IN the_DT U_NNP 0126_CD -_: treated_VBN cells_NNS ,_,
          approximately_RB 3_CD -_: 4_CD min_NN ,_, the_DT amplitude_NN of_IN the_DT [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN was_VBD slightly_RB higher_JJR (_( ~_NN 20_CD %_NN )_)
          in_IN the_DT U_NNP 0126_CD -_: treated_VBN cells_NNS ._. IONO_NNP elicited_JJ a_DT sustained_VBN ,_,
          supraphysiological_JJ [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN in_IN cells_NNS that_WDT was_VBD also_RB
          slightly_RB enhanced_VBN by_IN U_NNP 0126_CD (_( Fig_NNP ._. 3_LS Cand_NNP 3_CD D_NNP )_) ._. These_DT
          experiments_NNS demonstrate_VBP that_IN U_NNP 0126_CD does_VBZ not_RB decrease_VB [_NN Ca_MD
          2_CD +_NN ]_NN 
          i_NNP mobilization_NN ,_, and_CC the_DT inhibition_NN of_IN
          AA_NN release_NN by_IN U_NNP 0126_CD cannot_NN be_VB ascribed_VBN to_TO a_DT failure_NN in_IN
          [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP mobilization_NN ._.
        
        
          cPLA_NN 2_CD translocation_NN is_VBZ independent_JJ of_IN MEK_NNP 1_CD /_NN ERK_NNP
          pathway_NN
          The_DT effect_NN of_IN inhibition_NN of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN by_IN
          U_NNP 0126_CD on_IN translocation_NN of_IN cPLA_NN 
          2_CD was_VBD investigated_VBN ._. Although_IN there_EX is_VBZ
          no_DT inhibition_NN of_IN [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP release_NN by_IN U_NNP 0126_CD and_CC little_JJ effect_NN
          on_IN Ser_NNP 505_CD phosphorylation_NN ,_, it_PRP is_VBZ possible_JJ that_IN MEK_NNP 1_CD
          inhibition_NN by_IN U_NNP 0126_CD prevents_VBZ cPLA_NN 
          2_CD translocation_NN by_IN another_DT mechanism_NN ._.
          To_TO investigate_VB this_DT possibility_NN ,_, cells_NNS were_VBD transfected_JJ
          with_IN a_DT wild-type_JJ cPLA_NN 
          2_CD fused_JJ to_TO EYFP_NNP (_( EYFP-cPLA_NNP 
          2_LS )_) and_CC the_DT distribution_NN of_IN EYFP-cPLA_NNP 
          2_CD was_VBD imaged_JJ in_IN response_NN to_TO [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP transients_NNS elicited_JJ by_IN ATP_NNP and_CC
          sustained_VBN [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP elevations_NNS elicited_JJ by_IN IONO_NNP ,_, in_IN the_DT
          presence_NN and_CC absence_NN of_IN U_NNP 0126_CD ._. Following_VBG stimulation_NN with_IN
          100_CD μM_NN ATP_NNP ,_, there_EX was_VBD a_DT rapid_JJ translocation_NN of_IN EYFP-cPLA_NNP 
          2_CD to_TO Golgi_NNP that_WDT was_VBD unaffected_JJ by_IN
          U_NNP 0126_CD (_( Fig_NNP ._. 4_LS A_DT ,_, 4_CD B_NNP )_) ._. In_IN response_NN to_TO physiological_JJ agonists_NNS
          that_WDT elicit_NN transient_JJ [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP changes_NNS ,_, only_RB a_DT small_JJ fraction_NN of_IN
          the_DT cPLA_NN 
          2_CD translocates_NNS ._. This_DT observation_NN is_VBZ
          consistent_JJ with_IN our_PRP$ previous_JJ results_NNS [_NN 15_CD ]_NN and_CC has_VBZ been_VBN
          demonstrated_VBN by_IN Hirabayashi_NNP et_CC al_NN ._. [_NN 35_CD ]_NN ._. Most_JJS studies_NNS
          of_IN cPLA_NN 
          2_CD translocation_NN have_VBP utilized_JJ
          ionophore_NN ,_, which_WDT elicits_NNS a_DT large_JJ ,_, supraphysiological_JJ
          sustained_VBN increase_NN in_IN [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP [_NN 14_CD 15_CD 25_CD 35_CD 36_CD 37_CD 38_CD ]_NN ,_, or_CC
          agonists_NNS that_WDT produce_VBP a_DT sustained_VBN [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN [_NN 35_CD ]_NN ._. Under_IN these_DT
          conditions_NNS ,_, a_DT large_JJ proportion_NN of_IN cPLA_NN 
          2_CD binds_NNS to_TO membrane_NN ._. These_DT studies_NNS
          show_VBP extensive_JJ translocation_NN to_TO the_DT endoplasmic_JJ reticulum_NN
          (_( ER_NNP )_) ,_, nuclear_JJ envelope_NN and_CC Golgi_NNP [_NN 14_CD 15_CD 35_CD 36_CD 38_CD ]_NN ._. We_PRP
          found_VBD that_IN U_NNP 0126_CD also_RB failed_VBD to_TO alter_VB extensive_JJ EYFP-cPLA_NNP
          
          2_LS translocation_NN to_TO Golgi_NNP and_CC ER_NNP in_IN
          response_NN 10_CD μM_NN IONO_NNP (_( Fig_NNP ._. 4_LS C_NNP ,_, 4_CD D_NNP )_) ._. These_DT results_NNS
          demonstrate_VBP that_IN MEK_NNP inhibition_NN has_VBZ no_DT effect_NN on_IN cPLA_NN 
          2_CD translocation_NN ._.
        
        
          Translocation_NNP of_IN phosphorylation_NN site_NN mutants_NNS S_NNP 505_CD A_DT
          or_CC S_NNP 727_NNP A_DT is_VBZ similar_JJ as_IN wild-type_JJ cPLA_NN 2_CD
          Phosphorylation_NNP of_IN cPLA_NN 
          2_CD on_IN Ser_NNP 505_CD has_VBZ been_VBN hypothesized_VBN to_TO
          play_VB a_DT role_NN in_IN Ca_MD 2_CD +_NN -_: mediated_JJ translocation_NN since_IN Ser_NNP
          505_CD phosphorylation_NN is_VBZ required_VBN for_IN cPLA_NN 
          2_CD -_: mediated_JJ AA_NN release_NN in_IN response_NN to_TO
          low-dose_JJ ,_, but_CC not_RB high-dose_JJ ,_, ionophore_NN [_NN 22_CD ]_NN ._.
          Translocation_NNP of_IN cPLA_NN 
          2_CD S_NNP 505_CD A_DT in_IN CHO_NNP cells_NNS has_VBZ been_VBN reported_VBN
          in_IN response_NN to_TO ionophore_NN stimulation_NN [_NN 25_CD ]_NN ,_, but_CC the_DT
          effect_NN of_IN Ser_NNP 505_CD phosphorylation_NN on_IN the_DT kinetics_NNS of_IN
          translocation_NN ,_, targeting_VBG ,_, and_CC in_IN response_NN to_TO a_DT
          physiological_JJ agonist_NN was_VBD not_RB investigated_VBN ._. MDCK_NNP cells_NNS
          were_VBD co-transfected_JJ with_IN EYFP-cPLA_NNP 
          2_CD and_CC a_DT cPLA_NN 
          2_CD with_IN a_DT S_NNP 505_CD A_DT mutation_NN fused_JJ to_TO ECFP_NNP
          (_( ECFP-cPLA_NNP 
          2_CD S_NNP 505_CD A_DT )_) ._. Using_VBG dual_JJ EYFP_NNP /_NN ECFP_NNP
          imaging_NN ,_, we_PRP were_VBD able_JJ to_TO directly_RB compare_VB translocation_NN
          of_IN both_DT constructs_NNS in_IN the_DT same_JJ cell_NN ._. The_DT resting_VBG
          distribution_NN of_IN EYFP-cPLA_NNP 
          2_CD was_VBD similar_JJ to_TO that_DT of_IN ECFP-cPLA_NNP 
          2_CD S_NNP 505_CD A_DT and_CC ,_, in_IN response_NN to_TO ATP_NNP
          followed_VBN by_IN IONO_NNP ,_, the_DT pattern_NN of_IN translocation_NN of_IN
          EYFP-cPLA_NNP 
          2_CD was_VBD similar_JJ to_TO ECFP-cPLA_NNP 
          2_CD S_NNP 505_CD A_DT (_( Fig_NNP ._. 5_LS panels_NNS A_DT and_CC B_NNP ,_, D_NNP )_) ._.
          Analysis_NNP of_IN the_DT increase_NN in_IN fluorescence_NN at_IN the_DT Golgi_NNP
          with_IN respect_NN to_TO time_NN demonstrates_VBZ that_IN the_DT rates_NNS of_IN
          translocation_NN of_IN cPLA_NN 
          2_CD and_CC cPLA_NN 
          2_CD S_NNP 505_CD A_DT elicited_JJ by_IN ATP_NNP followed_VBN by_IN
          IONO_NNP are_VBP very_RB similar_JJ (_( Fig_NNP ._. 5_LS C_NNP )_) ._. As_IN previously_RB reported_VBD [_NN
          22_CD ]_NN ,_, the_DT cPLA_NN 
          2_CD S_NNP 727_NNP A_DT mutation_NN has_VBZ a_DT similar_JJ
          phenotype_NN on_IN AA_NN release_NN as_IN the_DT S_NNP 505_CD A_DT mutation_NN and_CC Ser_NNP
          727_NNP was_VBD found_VBN to_TO be_VB phosphorylated_JJ in_IN tandem_JJ with_IN Ser_NNP 505_CD ._.
          Imaging_NNP experiments_NNS were_VBD performed_VBN using_VBG EYFP-cPLA_NNP 
          2_CD and_CC ECFP-cPLA_NNP 
          2_CD S_NNP 727_NNP A_DT and_CC we_PRP found_VBD that_IN the_DT
          distribution_NN of_IN EYFP-cPLA_NNP 
          2_CD was_VBD identical_JJ to_TO that_DT of_IN ECFP-cPLA_NNP 
          2_CD S_NNP 727_NNP A_DT before_IN and_CC after_IN stimulation_NN
          with_IN 10_CD μM_NN IONO_NNP (_( Fig_NNP ._. 7_CD panels_NNS A_DT and_CC B_NNP ,_, D_NNP )_) ._. Analysis_NNP of_IN
          the_DT increase_NN in_IN fluorescence_NN at_IN the_DT Golgi_NNP with_IN respect_NN to_TO
          time_NN demonstrates_VBZ that_IN the_DT rates_NNS of_IN translocation_NN of_IN cPLA_NN
          
          2_LS and_CC the_DT cPLA_NN 
          2_CD S_NNP 727_NNP A_DT elicited_JJ by_IN IONO_NNP are_VBP very_RB
          similar_JJ (_( Fig_NNP ._. 6_CD C_NNP )_) ._.
        
      
      
        Discussion_NNP
        The_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN regulates_VBZ cPLA_NN 
        2_CD and_CC ERKs_NNP phosphorylate_NN cPLA_NN 
        2_CD on_IN Ser_NNP 505_CD ._. The_DT results_NNS of_IN this_DT study_NN
        demonstrate_VB that_IN this_DT pathway_NN is_VBZ required_VBN for_IN cPLA_NN 
        2_CD -_: mediated_JJ AA_NN release_NN independent_JJ of_IN
        Ser_NNP 505_CD phosphorylation_NN and_CC extend_VB our_PRP$ previous_JJ work_NN in_IN
        macrophages_NNS [_NN 13_CD ]_NN by_IN demonstrating_VBG that_IN this_DT alternative_JJ
        role_NN of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN is_VBZ not_RB involved_VBN in_IN regulating_VBG
        [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP change_NN or_CC cPLA_NN 
        2_CD translocation_NN kinetics_NNS or_CC targeting_VBG ,_,
        but_CC is_VBZ required_VBN for_IN optimal_NN hydrolytic_JJ activity_NN and_CC AA_NN
        release_NN ._.
        The_DT results_NNS shown_VBN here_RB demonstrate_VB that_DT inhibition_NN of_IN
        MEK_NNP with_IN U_NNP 0126_CD quantitatively_RB inhibits_NNS both_DT ERK_NNP
        phosphorylation_NN and_CC AA_NN release_NN in_IN MDCK_NNP cells_NNS in_IN response_NN to_TO
        [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP mobilization_NN ._. The_DT MEK_NNP inhibitor_NN
        PD_NNP 098059_CD ,_, a_DT less_RBR potent_JJ inhibitor_NN [_NN 28_CD 29_CD ]_NN ,_, also_RB
        inhibited_VBD ATP-_NNP and_CC IONO-induced_NNP AA_NN release_NN (_( data_NNS not_RB
        shown_VBN )_) ._. ERK_NNP was_VBD found_VBN to_TO be_VB constitutively_RB phosphorylated_JJ
        in_IN our_PRP$ study_NN using_VBG MDCK_NNP cells_NNS from_IN ATCC_NNP ,_, in_IN contrast_NN to_TO
        what_WP has_VBZ been_VBN reported_VBN previously_RB for_IN MDCK-D_NNP 
        1_CD ,_, a_DT subclone_NN of_IN MDCK_NNP selected_VBD for_IN
        adrenergic_JJ receptor_NN expression_NN [_NN 39_CD 40_CD ]_NN ._. However_RB ,_, a_DT
        side-by-side_RB comparison_NN of_IN MDCK_NNP cells_NNS from_IN ATCC_NNP and_CC the_DT
        MDCK-D_NNP 
        1_CD subclone_NN (_( kindly_RB provided_VBN by_IN Dr_NNP ._. Paul_NNP
        Insel_NNP ,_, UCSD_NNP )_) demonstrated_VBN constitutive_JJ activation_NN of_IN ERKs_NNP
        when_WRB both_DT are_VBP grown_VBN at_IN low_JJ density_NN (_( not_RB shown_VBN )_) ._. However_RB ,_, at_IN
        high_JJ density_NN ERKs_NNP are_VBP less_RBR active_JJ and_CC can_MD be_VB further_RBR
        activated_VBN by_IN phorbol_NN ester_NN (_( not_RB shown_VBN )_) ._.
        In_IN MDCK-D_NNP 

        1_LS cells_NNS ,_, without_IN constitutively_RB active_JJ
        ERKs_NNP ,_, AA_NN release_NN is_VBZ delayed_VBN after_IN [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP mobilization_NN ,_, and_CC is_VBZ temporally_RB
        correlated_JJ with_IN ERK_NNP activation_NN [_NN 40_CD ]_NN ,_, whereas_IN in_IN MDCK_NNP
        cells_NNS with_IN constitutively_RB active_JJ ERKs_NNP ,_, AA_NN release_NN is_VBZ rapid_JJ ,_,
        with_IN significant_JJ AA_NN release_NN measured_VBD 30_CD s_VBZ after_IN [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP increase_NN [_NN 15_CD ]_NN ._. This_DT temporal_JJ
        correlation_NN between_IN AA_NN release_NN and_CC ERK_NNP activation_NN has_VBZ also_RB
        been_VBN reported_VBN in_IN CHO_NNP cells_NNS in_IN response_NN to_TO PAF_NNP stimulation_NN [_NN
        35_CD 41_CD ]_NN ._. These_DT results_NNS support_VBP the_DT observations_NNS made_VBN here_RB
        that_IN ERK_NNP activity_NN is_VBZ required_VBN for_IN phospholipid_NN hydrolysis_NNS
        independently_RB of_IN cPLA_NN 
        2_CD translocation_NN ._.
        cPLA_NN 
        2_CD -_: mediated_JJ AA_NN release_NN must_MD be_VB preceded_VBN
        by_IN translocation_NN of_IN the_DT enzyme_NN to_TO its_PRP$ membrane_NN substrate_NN
        which_WDT is_VBZ a_DT Ca_MD 2_CD +_NN -_: dependent_JJ process_NN and_CC is_VBZ a_DT function_NN of_IN the_DT
        calcium-dependent_JJ lipid-binding_JJ (_( C_NNP 2_LS )_) domain_NN ._. cPLA_NN 
        2_CD translocates_NNS primarily_RB to_TO Golgi_NNP in_IN
        response_NN to_TO a_DT transient_JJ [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP changes_NNS and_CC to_TO Golgi_NNP and_CC ER_NNP in_IN
        response_NN to_TO a_DT sustained_VBN [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP increase_NN [_NN 15_CD ]_NN ._. The_DT reduction_NN in_IN AA_NN
        release_NN by_IN MEK_NNP inhibition_NN did_VBD not_RB involve_VB a_DT failure_NN in_IN [_NN Ca_MD
        2_CD +_NN ]_NN 
        i_NNP release_NN or_CC translocation_NN ._. These_DT
        results_NNS show_VBP that_DT translocation_NN is_VBZ necessary_JJ but_CC not_RB
        sufficient_JJ for_IN optimum_JJ hydrolytic_JJ activity_NN ._.
        Measuring_NN cPLA_NN 
        2_CD translocation_NN is_VBZ not_RB a_DT trivial_JJ matter_NN
        when_WRB investigating_VBG mechanisms_NNS of_IN AA_NN release_NN ._. For_IN example_NN ,_,
        cPLA_NN 
        2_CD constructs_NNS with_IN a_DT S_NNP 505_CD A_DT mutation_NN have_VBP
        long_RB been_VBN recognized_VBN as_IN unable_JJ to_TO support_VB AA_NN release_NN in_IN
        response_NN to_TO physiological_JJ agonists_NNS or_CC low-dose_JJ ionophore_NN
        when_WRB transfected_JJ in_IN cells_NNS ._. In_IN contrast_NN ,_, cPLA_NN 
        2_CD S_NNP 505_CD A_DT is_VBZ active_JJ in_IN vitro_NN and_CC
        phosphorylation_NN only_RB modestly_RB increases_VBZ the_DT activity_NN of_IN the_DT
        enzyme_NN [_NN 16_CD 17_CD 24_CD ]_NN ._. Interestingly_RB ,_, the_DT inhibitory_NN effect_NN
        of_IN the_DT S_NNP 505_CD A_DT mutation_NN on_IN AA_NN release_NN is_VBZ obviated_JJ by_IN a_DT high_JJ
        [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP increase_NN ._. In_IN light_NN of_IN these_DT
        observations_NNS ,_, it_PRP is_VBZ possible_JJ that_IN Ser_NNP 505_CD phosphorylation_NN
        may_MD alter_VB the_DT [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP sensitivity_NN of_IN the_DT enzyme_NN ,_, its_PRP$ rate_NN of_IN
        translocation_NN ,_, its_PRP$ intracellular_NN targeting_VBG or_CC ,_, as_IN has_VBZ been_VBN
        previously_RB suggested_VBN [_NN 22_CD ]_NN ,_, the_DT ability_NN of_IN cPLA_NN 
        2_CD to_TO release_VB from_IN a_DT non-membrane_JJ
        sequestering_NN agent_NN ._. Although_IN one_CD report_NN has_VBZ shown_VBN that_DT cPLA_NN
        
        2_LS S_NNP 505_CD A_DT translocates_NNS in_IN CHO_NNP cells_NNS in_IN
        response_NN to_TO ionophore_NN ,_, we_PRP were_VBD able_JJ to_TO directly_RB compare_VB
        rates_NNS of_IN translocation_NN between_IN cPLA_NN 
        2_CD and_CC cPLA_NN 
        2_CD S_NNP 505_CD A_DT to_TO a_DT physiological_JJ agonist_NN and_CC
        found_VBD no_DT difference_NN between_IN translocation_NN rates_NNS or_CC
        intracellular_NN targeting_VBG ._. We_PRP also_RB demonstrated_VBD that_IN there_EX
        was_VBD no_DT difference_NN in_IN translocation_NN rates_NNS or_CC intracellular_NN
        targeting_VBG between_IN wild-type_JJ cPLA_NN 
        2_CD and_CC cPLA_NN 
        2_CD S_NNP 727_NNP A_DT ,_, which_WDT has_VBZ the_DT same_JJ phenotype_NN as_IN
        S_NNP 505_CD A_DT with_IN regard_NN to_TO AA_NN release_NN when_WRB transfected_JJ into_IN
        cells_NNS ._. Thus_RB ,_, the_DT role_NN of_IN cPLA_NN 
        2_CD phosphorylation_NN in_IN mediating_VBG AA_NN
        release_NN remains_VBZ unclear_JJ ._.
        Although_IN the_DT alternative_JJ mechanism_NN whereby_WRB the_DT MEK_NNP 1_CD /_NN ERK_NNP
        pathway_NN regulates_VBZ cPLA_NN 
        2_CD is_VBZ not_RB known_VBN ,_, it_PRP is_VBZ possible_JJ that_IN it_PRP
        affects_VBZ membrane_NN properties_NNS and_CC /_NN or_CC cPLA_NN 
        2_CD conformation_NN that_WDT promotes_VBZ optimal_NN
        hydrolytic_JJ activity_NN ._. It_PRP is_VBZ also_RB possible_JJ that_IN the_DT
        alternative_JJ mechanism_NN is_VBZ due_JJ to_TO phosphorylation_NN of_IN cPLA_NN 
        2_CD on_IN a_DT novel_NN site_NN by_IN a_DT kinase_NN that_WDT is_VBZ
        downstream_JJ of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN or_CC phosphorylation_NN of_IN a_DT
        regulatory_JJ protein_NN ._.
      
      
        Conclusions_NNP
        Translocation_NNP to_TO membrane_NN is_VBZ a_DT critical_JJ regulatory_JJ step_NN
        for_IN the_DT action_NN of_IN cPLA_NN 
        2_CD because_IN it_PRP is_VBZ necessary_JJ for_IN access_NN to_TO
        substrate_NN ._. In_IN this_DT study_NN we_PRP demonstrate_VBP ,_, however_RB ,_, that_DT
        association_NN of_IN cPLA_NN 
        2_CD with_IN membrane_NN when_WRB phosphorylated_JJ on_IN
        Ser_NNP 505_CD is_VBZ not_RB sufficient_JJ for_IN its_PRP$ full_JJ activity_NN in_IN vivo_NN ._.
        This_DT is_VBZ demonstrated_VBN by_IN the_DT results_NNS showing_VBG that_DT inhibition_NN
        of_IN the_DT MEK_NNP 1_CD /_NN ERK_NNP pathway_NN significantly_RB blocks_VBZ AA_NN release_NN but_CC
        has_VBZ no_DT effect_NN on_IN [_NN Ca_MD 2_CD +_NN ]_NN 
        i_NNP mobilization_NN or_CC cPLA_NN 
        2_CD translocation_NN and_CC targeting_VBG ._.
        Diminution_NNP of_IN AA_NN release_NN by_IN MEK_NNP 1_CD /_NN ERK_NNP is_VBZ also_RB independent_JJ of_IN
        cPLA_NN 
        2_CD phosphorylation_NN on_IN Ser_NNP 505_CD ._.
        Consequently_RB ,_, our_PRP$ results_NNS demonstrate_VBP in_IN living_VBG cells_NNS that_IN
        the_DT translocation_NN process_NN and_CC subsequent_JJ catalytic_JJ activity_NN
        on_IN the_DT membrane_NN are_VBP two_CD independently_RB regulated_VBN steps_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Fluorescent_NNP protein-c_JJ PLA_NNP 2_CD fusion_NN constructs_NNS
          DNA_NNP encoding_VBG the_DT full-length_JJ human_JJ cPLA_NN 
          2_CD was_VBD cloned_VBN into_IN the_DT vector_NN pEGFP-C_JJ 3_CD
          (_( Clontech_NNP )_) to_TO create_VB pEGFP-cPLA_JJ 
          2_CD ,_, as_RB previously_RB described_VBD [_NN 15_CD ]_NN ._.
          The_DT XbaI_NNP /_NN PstI_NNP fragment_NN from_IN a_DT cPLA_NN 
          2_CD α_NN clone_NN containing_VBG S_NNP 505_CD A_DT or_CC S_NNP 727_NNP A_DT
          mutations_NNS [_NN 13_CD ]_NN was_VBD inserted_VBN into_IN an_DT XbaI_NNP /_NN PstI_NNP site_NN in_IN
          pEGFP-cPLA_JJ 
          2_CD to_TO generate_VB pEGFP-cPLA_JJ 
          2_CD S_NNP 505_CD A_DT and_CC pECFP-cPLA_JJ 
          2_CD S_NNP 727_NNP A_DT ._. Different_JJ fluorescent-protein_JJ
          tagged_VBN constructs_NNS were_VBD produced_VBN by_IN exchanging_VBG the_DT
          NheI_NNP /_NN BsrGI_NNP fragment_NN containing_VBG the_DT fluorescent_NN protein_NN
          coding_VBG sequence_NN between_IN EGFP_NNP ,_, EYFP_NNP ,_, and_CC ECFP_NNP ._. All_DT
          constructs_NNS were_VBD confirmed_VBN by_IN sequencing_VBG ._.
        
        
          Cell_NNP culture_NN
          MDCK_NNP cells_NNS obtained_VBN from_IN ATCC_NNP were_VBD cultured_JJ in_IN DMEM_NNP
          containing_VBG 10_CD %_NN FBS_NNP ,_, 100_CD U_NNP /_NN ml_NN penicillin_NN ,_, 100_CD μg_NN /_NN ml_NN
          streptomycin_NN ,_, 0_CD ._. 292_CD mg_NN /_NN ml_NN glutamine_NN (_( growth_NN medium_NN )_) in_IN 5_CD %_NN
          CO_NNP 
          2_CD at_IN 37_CD °_NN C_NNP ._. Subconfluent_NNP cells_NNS (_( 5_CD ×_NN 10_CD
          3_CD cells_NNS /_NN cm_NN 2_LS )_) were_VBD transfected_JJ with_IN 2_CD μg_NN of_IN the_DT relevant_JJ
          plasmid_NN using_VBG Fugene-_NNP 6_CD (_( Boehringer_NNP Mannheim_NNP )_) in_IN DMEM_NNP
          containing_VBG 0_CD ._. 2_CD %_NN BSA_NNP ,_, 100_CD U_NNP /_NN ml_NN penicillin_NN ,_, 100_CD μg_NN /_NN ml_NN
          streptomycin_NN ,_, 0_CD ._. 292_CD mg_NN /_NN ml_NN glutamine_NN (_( serum-free_JJ medium_NN )_)
          following_VBG the_DT manufacturer_NN 's_POS protocol_NN ._. Stable_NNP lines_NNS
          expressing_VBG EGFP-cPLA_NNP 
          2_CD were_VBD generated_VBN by_IN growing_VBG
          transfected_JJ cells_NNS in_IN growth_NN medium_NN for_IN 3_CD d_SYM ,_, supplementing_VBG
          the_DT growth_NN medium_NN with_IN 5_CD mg_NN /_NN ml_NN Geneticin_NNP (_( antibiotic_JJ
          G_NNP 418_CD -_: sulfate_NN )_) ,_, and_CC culturing_VBG for_IN an_DT additional_JJ 2_CD wk_NN in_IN
          Geneticin_NNP ._. Cells_NNP expressing_VBG EGFP_NNP fluorescence_NN were_VBD
          selected_VBN using_VBG a_DT fluorescence-activated_JJ cell_NN sorter_NN ._. The_DT
          EGFP-positive_NNP cells_NNS were_VBD maintained_VBN in_IN growth_NN medium_NN
          supplemented_JJ with_IN 5_CD mg_NN /_NN ml_NN Geneticin_NNP ._. For_IN imaging_NN studies_NNS ,_,
          MDCK_NNP cells_NNS were_VBD plated_JJ on_IN glass-bottomed_JJ 35_CD mm_NN culture_NN
          dishes_NNS (_( MatTek_NNP )_) at_IN 5_CD ×_NN 10_CD 3_CD cells_NNS /_NN cm_NN 2_CD in_IN growth_NN medium_NN and_CC
          incubated_JJ overnight_JJ ,_, transfected_JJ with_IN the_DT relevant_JJ
          plasmid_NN (_( s_VBZ )_) ,_, changed_VBN into_IN serum-free_JJ medium_NN to_TO quiesce_NN the_DT
          cells_NNS ,_, incubated_JJ overnight_JJ ,_, and_CC used_VBD the_DT next_JJ day_NN ._.
        
        
          Immunoblotting_NNP
          Stable_NNP EGFP-cPLA_NNP 
          2_CD transfectants_NNS were_VBD grown_VBN on_IN 100_CD mm_NN
          dishes_NNS at_IN 5_CD ×_NN 10_CD 3_CD cells_NNS /_NN cm_NN 2_CD in_IN growth_NN medium_NN for_IN one_CD day_NN ,_,
          then_RB quiesced_JJ in_IN serum-free_JJ medium_NN overnight_JJ ._. Cells_NNP were_VBD
          scraped_JJ into_IN ice-cold_JJ lysis_NNS buffer_NN :_: 50_CD mM_NN HEPES_NNP ,_, pH_NN 7_CD ._. 4_CD ,_,
          150_CD mM_NN sodium_NN chloride_NN ,_, 1_CD ._. 5_CD mM_NN magnesium_NN chloride_NN ,_, 10_CD %_NN
          glycerol_NN ,_, 1_CD %_NN Triton_NNP X-_NNP 100_CD ,_, 1_CD mM_NN EGTA_NNP ,_, 200_CD μM_NN sodium_NN
          vanadate_NN ,_, 10_CD mM_NN tetrasodium_NN pyrophosphate_NN ,_, 100_CD mM_NN sodium_NN
          fluoride_NN ,_, 10_CD μg_NN /_NN ml_NN leupeptin_NN ,_, and_CC 10_CD μg_NN /_NN ml_NN aprotinin_NN ._.
          Lysates_NNP were_VBD centrifuged_JJ at_IN 15_CD ,_, 000_CD ×_NN 
          g_SYM for_IN 15_CD min_NN ,_, and_CC protein_NN
          concentration_NN of_IN the_DT supernatant_NN was_VBD determined_VBN by_IN the_DT
          bicinchoninic_JJ acid_NN method_NN ._. Laemmli_NNP electrophoresis_NNS sample_NN
          buffer_NN (_( 5_CD ×_NN )_) was_VBD added_VBN to_TO the_DT lysates_NNS ,_, and_CC
          SDS-polyacrylamide_NNP gel_NN electrophoresis_NNS and_CC immunoblotting_VBG
          were_VBD performed_VBN using_VBG 35_CD μg_NN lysate_NN protein_NN ,_,
          phospho-specific_JJ antibodies_NNS for_IN ERK_NNP and_CC p_NN 38_CD ,_, and_CC rabbit_NN
          polyclonal_NN antibody_NN for_IN cPLA_NN 
          2_CD [_NN 21_CD ]_NN ._.
        
        
          Dual_JJ imaging_NN microscopy_NN of_IN fluorescent_NN protein_NN
          translocation_NN
          In_IN order_NN to_TO compare_VB the_DT characteristics_NNS of_IN full-length_JJ
          cPLA_NN 
          2_CD and_CC cPLA_NN 
          2_CD S_NNP 505_CD A_DT or_CC cPLA_NN 
          2_CD S_NNP 727_NNP A_DT translocation_NN ,_, while_IN
          controlling_VBG for_IN cell-to-cell_JJ heterogeneity_NN ,_, we_PRP used_VBD a_DT
          dual_JJ CFP_NNP /_NN YFP_NNP imaging_NN approach_NN ._. EYFP-cPLA_NNP 
          2_CD /_NN ECFP-cPLA_NNP 
          2_CD S_NNP 505_CD A-_NNP or_CC pECFP-cPLA_JJ 
          2_CD S_NNP 727_NNP A-_NNP transfected_JJ MDCK_NNP cells_NNS grown_VBN
          on_IN MatTek_NNP plates_NNS were_VBD quiesced_JJ overnight_JJ in_IN serum-free_JJ
          medium_NN ,_, washed_VBN with_IN and_CC incubated_JJ in_IN Hank_NNP 's_POS balanced_JJ salt_NN
          solution_NN (_( HBSS_NNP )_) additionally_RB buffered_JJ with_IN 25_CD mM_NN HEPES_NNP pH_NN
          7_CD ._. 4_CD (_( HHBSS_NNP )_) ._. Cells_NNP were_VBD imaged_JJ using_VBG an_DT Olympus_NNP inverted_JJ
          microscope_NN equipped_VBN with_IN a_DT 60_CD ×_NN ,_, 1_CD ._. 25_CD NA_NNP oil_NN immersion_NN
          objective_NN ,_, CFP_NNP and_CC YFP_NNP emission_NN filters_NNS (_( Chroma_NNP )_) in_IN a_DT
          Sutter_NNP filter_NN wheel_NN ,_, a_DT dual_JJ CFP_NNP /_NN YFP_NNP dichroic_JJ mirror_VBP ,_, and_CC
          a_DT TILL_NNP Imago_NNP CCD_NNP camera_NN (_( TILL_NNP Photonics_NNP )_) ._. Excitation_NNP
          light_NN of_IN 430_CD and_CC 510_CD nm_NN for_IN CFP_NNP and_CC YFP_NNP ,_, respectively_RB ,_,
          was_VBD provided_VBN using_VBG a_DT Polychrome_NNP IV_NNP monochromator_NN (_( TILL_NNP
          Photonics_NNP )_) ._. TILLvisION_NNP software_NN was_VBD used_VBN for_IN acquisition_NN
          and_CC analysis_NN ._. Bleach_NN values_NNS for_IN ECFP_NNP and_CC EYFP_NNP were_VBD
          calculated_VBN by_IN determining_VBG the_DT background-corrected_JJ
          fluorescence_NN for_IN the_DT entire_JJ cell_NN with_IN respect_NN to_TO time_NN and_CC
          normalizing_VBG each_DT value_NN to_TO the_DT initial_JJ value_NN ._. ECFP_NNP /_NN EYFP_NNP
          fluorescence_NN changes_NNS with_IN respect_NN to_TO time_NN for_IN regions_NNS of_IN
          interest_NN corresponding_JJ to_TO an_DT area_NN of_IN Golgi_NNP membrane_NN were_VBD
          determined_VBN by_IN calculating_VBG the_DT F_NN 
          t_NN /_NN F_NN 
          0_CD ,_, where_WRB F_NN 
          t_NN is_VBZ the_DT background-_NN and_CC
          bleach-corrected_JJ ECFP_NNP or_CC EYFP_NNP fluorescence_NN at_IN time_NN =_SYM t_NN
          and_CC F_NN 
          0_CD is_VBZ the_DT background-corrected_JJ ECFP_NNP or_CC
          EYFP_NNP fluorescence_NN at_IN time_NN =_SYM 0_CD s_VBZ ._. Fluorescence_NNP was_VBD
          normalized_JJ to_TO the_DT F_NN 
          0_CD value_NN ,_, which_WDT resulted_VBD in_IN F_NN 
          t_NN /_NN F_NN 
          0_CD representing_VBG the_DT fraction_NN of_IN total_JJ
          cell_NN fluorescence_NN at_IN Golgi_NNP ._. Final_JJ images_NNS were_VBD produced_VBN
          using_VBG Adobe_NNP Photoshop_NNP ._.
        
        
          Calcium_NNP imaging_NN
          MDCK_NNP cells_NNS grown_VBN on_IN MatTek_NNP plates_NNS were_VBD quiesced_JJ
          overnight_JJ in_IN serum-free_JJ medium_NN ,_, washed_VBN with_IN HHBSS_NNP
          containing_VBG 1_CD mM_NN probenecid_NN and_CC incubated_JJ with_IN 5_CD μM_NN
          Fura_NNP 2_CD -_: AM_NNP (_( Calbiochem_NNP )_) in_IN HHBSS_NNP ,_, 1_CD mM_NN probenecid_NN ,_, and_CC 1_CD %_NN
          DMSO_NNP for_IN 45_CD min_NN at_IN 37_CD °_NN C_NNP ._. Cells_NNP were_VBD then_RB washed_VBN with_IN
          HHBSS_NNP containing_VBG 1_CD mM_NN probenecid_NN and_CC imaged_JJ after_IN a_DT 30_CD
          min_NN incubation_NN for_IN de-esterification_JJ of_IN the_DT Fura_NNP 2_CD -_: AM_NNP ._.
          Single-cell_JJ imaging_NN was_VBD performed_VBN on_IN the_DT Olympus_NNP system_NN
          described_VBD above_IN ,_, but_CC using_VBG a_DT 40_CD ×_NN ,_, 1_CD ._. 35_CD NA_NNP oil_NN immersion_NN
          objective_NN and_CC a_DT Fura_NNP 2_CD dichroic_JJ mirror_VBP and_CC emission_NN filter_NN
          (_( Chroma_NNP )_) ._. Fura_NNP 2_CD image_NN pairs_NNS illuminated_JJ at_IN 340_CD and_CC 380_CD nm_NN
          were_VBD taken_VBN at_IN 1_CD Hz_NNP ._. The_DT [_NN Ca_MD 2_CD +_NN ]_NN 
          i_NNP increase_NN is_VBZ expressed_VBN as_IN the_DT ratio_NN
          of_IN the_DT background-corrected_JJ Fura_NNP 2_CD fluorescence_NN at_IN 340_CD and_CC
          380_CD nm_NN [_NN 42_CD ]_NN ._.
        
        
          Measurement_NNP of_IN AA_NN release_NN
          The_DT protocol_NN for_IN determining_VBG AA_NN release_NN is_VBZ essentially_RB
          as_IN described_VBN [_NN 15_CD 21_CD ]_NN ._. MDCK_NNP cells_NNS stably_RB expressing_VBG
          EGFP-cPLA_NNP 
          2_CD were_VBD plated_JJ in_IN 12_CD -_: well_RB plates_NNS at_IN 5_CD ×_NN
          10_CD 3_CD cells_NNS /_NN cm_NN 2_CD and_CC incubated_JJ in_IN growth_NN medium_NN overnight_JJ ._.
          Cells_NNP were_VBD then_RB washed_VBN twice_RB with_IN serum-free_JJ medium_NN and_CC
          incubated_JJ with_IN 0_CD ._. 25_CD μCi_NN [_NN 3_CD H_NNP ]_NN -_: AA_NN /_NN well_RB in_IN serum-free_JJ
          medium_NN overnight_JJ ._. U_NNP 0126_CD or_CC vehicle_NN was_VBD added_VBN to_TO each_DT well_RB
          and_CC the_DT cells_NNS were_VBD then_RB incubated_JJ for_IN 15_CD min_NN at_IN 37_CD °_NN C_NNP in_IN
          5_CD %_NN CO_NNP 
          2_CD ._. Cells_NNP were_VBD washed_VBN to_TO remove_VB
          unincorporated_JJ [_NN 3_CD H_NNP ]_NN -_: AA_NN and_CC then_RB incubated_JJ in_IN HHBSS_NNP
          supplemented_JJ with_IN 0_CD ._. 05_CD %_NN BSA_NNP with_IN either_DT U_NNP 0126_CD or_CC vehicle_NN ._.
          Cells_NNP were_VBD stimulated_VBN with_IN the_DT agonist_NN of_IN choice_NN and_CC the_DT
          medium_NN was_VBD collected_VBN at_IN appropriate_JJ time_NN points_NNS ._. The_DT
          medium_NN was_VBD centrifuged_JJ at_IN 500_CD g_SYM for_IN 5_CD min_NN ,_, and_CC the_DT amount_NN
          of_IN radioactivity_NN in_IN the_DT supernatant_NN was_VBD determined_VBN by_IN
          scintillation_NN counting_NN ._. Cells_NNP were_VBD scraped_JJ in_IN 0_CD ._. 5_CD ml_NN 0_CD ._. 1_CD %_NN
          Triton_NNP X-_NNP 100_CD for_IN determining_VBG the_DT total_JJ cellular_JJ
          radioactivity_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        JHE_NNP carried_VBD out_RP the_DT Ca_MD and_CC FP_NNP imaging_NN studies_NNS ,_,
        participated_VBD in_IN the_DT design_NN and_CC coordination_NN of_IN the_DT study_NN ,_,
        and_CC drafted_VBD the_DT manuscript_NN ._. DJF_NNP performed_VBD the_DT AA_NN release_NN
        and_CC Western_JJ blot_NN studies_NNS and_CC participated_VBD in_IN the_DT design_NN and_CC
        coordination_NN of_IN the_DT study_NN ._. CCL_NNP conceived_VBD of_IN the_DT study_NN ,_,
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ,_, and_CC
        participated_VBD in_IN writing_VBG the_DT draft_NN ._. All_DT authors_NNS read_VBP and_CC
        approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
